diclofenac and rifamycins

diclofenac has been researched along with rifamycins in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akaki, T; Kawahara, S; Sato, K; Shimizu, T; Tomioka, H	1
Kawahara, S; Kawauchi, H; Sano, C; Sato, K; Shimizu, T; Tomioka, H	1
Bjarnason, I; Dolak, W; Grimaldi, M; Lanas, A; Matzneller, P; Renzulli, C; Scarpignato, C; Zeitlinger, M	1

Trials

1 trial(s) available for diclofenac and rifamycins

Article	Year
Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans. Gastroenterology, 2017, Volume: 152, Issue:5 Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Delayed-Action Preparations; Diclofenac; Double-Blind Method; Female; Gastrointestinal Microbiome; Humans; Intestinal Mucosa; Intestine, Small; Logistic Models; Male; Omeprazole; Proton Pump Inhibitors; Rifamycins; Rifaximin; Severity of Illness Index; Ulcer	2017

Article

Year

Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans.

Gastroenterology, 2017, Volume: 152, Issue:5

Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Delayed-Action Preparations; Diclofenac; Double-Blind Method; Female; Gastrointestinal Microbiome; Humans; Intestinal Mucosa; Intestine, Small; Logistic Models; Male; Omeprazole; Proton Pump Inhibitors; Rifamycins; Rifaximin; Severity of Illness Index; Ulcer

2017

Other Studies

2 other study(ies) available for diclofenac and rifamycins

Article	Year
[In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice]. Kekkaku : [Tuberculosis], 1997, Volume: 72, Issue:8 Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Clarithromycin; Diclofenac; Drug Therapy, Combination; Female; Levofloxacin; Mice; Mice, Inbred BALB C; Mycobacterium avium; Ofloxacin; Rifamycins; Tuberculosis	1997
Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection i Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Cytokines; Diclofenac; Drug Therapy, Combination; Mice; Mice, Inbred BALB C; Mycobacterium avium Complex; Protease Inhibitors; Rifamycins; Tuberculosis	1999

Article

Year

[In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].

Kekkaku : [Tuberculosis], 1997, Volume: 72, Issue:8

Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Clarithromycin; Diclofenac; Drug Therapy, Combination; Female; Levofloxacin; Mice; Mice, Inbred BALB C; Mycobacterium avium; Ofloxacin; Rifamycins; Tuberculosis

1997

Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection i

Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:2

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Cytokines; Diclofenac; Drug Therapy, Combination; Mice; Mice, Inbred BALB C; Mycobacterium avium Complex; Protease Inhibitors; Rifamycins; Tuberculosis

1999